Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for USTEKINUMAB
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule
- Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
- Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
- Biologics and Blistering
- LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
- An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
- A Study of Ustekinumab in Pediatric Participants
- Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
- A Long-term Extension Study of Ustekinumab in Pediatric Participants
- A Study of Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- COVID-19 VaccinE Response in Rheumatology Patients
- A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
- Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
- A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
- Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
- A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
- Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults
- A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
- Stelara and Diet Trial for Crohn"s Disease
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects
- A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Induction Optimization With Stelara for Crohn's Disease
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
- Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant
- An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
- Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
- A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
- Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
- Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
- Loss of RESponse to Ustekinumab Treated by Dose Escalation
- PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
- Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
- Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
- Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
- A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
- Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants
- A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
- Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
- Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
- Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
- Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
- A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
- A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
- An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
- Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
- A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Ustekinumab for the Treatment of Giant Cell Arteritis
- Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
- Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
- Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
- An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
- The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
- BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
- A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
- An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
- A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
- Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
- Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
- Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
- A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
- Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
- A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- An Exploratory Genetic Study in Participants With Psoriasis
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D
- Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
- BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
- A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
- Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
- Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
- Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
- Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
- P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
- Swiss Dermatology Network of Targeted Therapies (SDNTT)
- A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa
- A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries
- Ustekinumab for Active Sight-Threatening Uveitis
- A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
- A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis
- A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
- The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
- A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
- Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
- Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis
- A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
- Psoriasis Inflammation and Systemic Co Morbidities
- Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis
- A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
- Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
- Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
- A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects
- A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
- A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
- A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
- A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
- A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
- A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
- A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
- An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
- Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
- A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
- A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
- An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
- A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
Clinical trials list
click for details